Cancer Immunology and Immunotherapy
A section of Cancers (ISSN 2072-6694).
Section Information
Cancer remains a leading cause of death in Western countries, and treatment of advanced stages of the disease is still limited. Discoveries in the field of cancer immunology and progress in immunotherapy as the first line therapy bring the most exciting times for delivering a potential cure for advanced cancer. Understanding the common mechanisms of tumorigenesis, including changes in tumor microenvironment, immune evasion, and antitumor immune responses, is pivotal for further development of novel therapeutics.
Following early discoveries of connection of autoimmune diseases with cancer, recent advances in T cell biology have revolutionized cancer therapy. Most importantly, standard-of-care chemotherapy and radiation effects have also been linked to immune cell-mediated anticancer effects.
Importantly, multiple clinical trials using checkpoint blockade agents, ATC transfer therapies, and cancer vaccines show much better outcomes than the most effective chemotherapeutic agents.
The aim of this Special Section is to publish findings that relate to cancer immunology and therapies based on the immune-targeting. Topics include, but are not limited to:
- checkpoint blockade
- innate immunity
- adaptive responses
- vaccines
- ATC transfer therapy
- immune evasion
- immune switch
- immunosuppression
- tumor microenvironment
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- B Cells and Antibody Responses in Cancers (Deadline: 26 April 2024)
- Immunotherapy with Checkpoint Inhibitors for Non-small Cell Lung Cancer (Deadline: 30 April 2024)
- Emerging Biomarkers and Therapeutic Targets in Cancer Immunotherapy (Deadline: 30 April 2024)
- Tumor-Associated Macrophages in Primary Liver Cancers and in Premalignant Liver Diseases (Deadline: 1 May 2024)
- Research Progress of Cutaneous Squamous and Basal Cell Carcinomas (Volume II) (Deadline: 15 May 2024)
- Inflammation, Immunity, and Cancer Progression (Deadline: 31 May 2024)
- Immunotherapy for Cancers (Deadline: 31 May 2024)
- The Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion (Volume II) (Deadline: 1 June 2024)
- Anticancer Immunity with Physical Treatment Modalities (Deadline: 1 June 2024)
- Cancer and Immunomediated Inflammatory Diseases (IMIDs) (Deadline: 10 June 2024)
- State-of-the-Art Cancer Immunology and Immunotherapy in the USA (Deadline: 20 June 2024)
- Diagnosis, Molecular Classification, and Treatment of T-Cell Lymphomas (Deadline: 25 June 2024)
- Immune Checkpoint Inhibitor-Based Immunotherapy in Cancer: Predictive Biomarkers and Mechanisms of Resistance (Deadline: 30 June 2024)
- Clinical and Immunological Therapy for Solid Tumors (Deadline: 30 June 2024)
- Immunosuppression and Protective Immunity in Tumor Microenvironment (Deadline: 30 June 2024)
- Monoclonal Antibodies in Lymphoma (Deadline: 30 June 2024)
- Immune Checkpoint Inhibitors for Urologic Cancers (Deadline: 30 June 2024)
- Combination Immunotherapy for Cancer Treatment (Deadline: 30 June 2024)
- Female Malignancies and Immunotherapy: What’s New? (Volume II) (Deadline: 5 July 2024)
- Oncolytic Viruses: A Key Step toward Cancer Immunotherapy (Deadline: 15 July 2024)
- T-Cells and Cancer: Recent Advances and Updates (Deadline: 15 July 2024)
- How to Properly Diagnose and Treat Immune-Related Adverse Events during Immunotherapy in Patients with Cancer: Discussion between Specialists (Deadline: 15 July 2024)
- Immunotherapy for Multiple Myeloma (Deadline: 15 July 2024)
- Cancer Immunotherapy: Therapeutics and Mechanisms (Deadline: 30 July 2024)
- Cancers Precision Immunotherapy (Deadline: 31 July 2024)
- T Cell and Tumor Immunotherapy (Deadline: 31 July 2024)
- Research of Anti-tumor Immune Responses to Gastrointestinal (GI) Cancers (Deadline: 31 July 2024)
- Topical and Intralesional Immunotherapy for Skin Cancer (Deadline: 31 July 2024)
- Targeting Immune Checkpoints for Cancer Therapy: Potential and Challenges (Deadline: 15 August 2024)
- Updates on Mechanism and Management of Gynecological Cancer (Deadline: 25 August 2024)
- Recent Advances in Nanomedicine-Based Cancer Immunotherapy (Deadline: 31 August 2024)
- Oncolytic Viruses as an Emerging Aspect of Immune Oncology (Deadline: 31 August 2024)
- Role of Immune Checkpoint Inhibitors or Targeted Therapy in the Treatment of Patients with Melanoma Volume II (Deadline: 20 September 2024)
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors (Deadline: 30 September 2024)
- Immunomodulation in Cancer Treatment (Deadline: 30 September 2024)
- Mechanisms of Cancer Cells Escape from Immune Surveillance: The Focus on Epigenetic and Pro-inflammatory Adaptations (Deadline: 30 September 2024)
- The Tumor–Immune Interface for Next-Generation Immunotherapy (Deadline: 30 September 2024)
- Immunotherapy Approaches in Breast Cancer Treatment (Deadline: 30 September 2024)
- Personalized Immunotherapy for Cancers (Deadline: 1 October 2024)
- Evidence from the Real World Provides New Insights into the Evolving Landscape of Cancer Immunotherapy (Deadline: 31 October 2024)
- NK Cells in the Tumor Microenvironment: Immunosuppressive Mechanisms and Therapy (Deadline: 22 November 2024)
- State-of-the-Art Research on Multiple Myeloma Progression (Deadline: 30 November 2024)
- Quantitative Image Tissue Analysis Based on Multiplexed Platforms for Immuno-Oncology Applications (Deadline: 30 November 2024)
- New Insights of Hematology in Cancer (Deadline: 30 November 2024)
- Microenvironment and Metastasis in Breast and Gynecological Tumors (Deadline: 30 November 2024)
- Immunotherapy in the Management of Hematologic Malignancy (Deadline: 30 November 2024)
- Innovative Immunotherapies: CAR-T Cell Therapy for Cancers (Deadline: 13 December 2024)
- The Role of Immunotherapy in Hematological Malignancies Volume II (Deadline: 15 December 2024)
- Immunotherapy in Non-small Cell Lung Cancers (Deadline: 22 December 2024)
- Research on Cell Death in Cancer Immunotherapy (Deadline: 25 December 2024)
- Macrophage-Directed Cancer Immunotherapy (Deadline: 31 December 2024)
- IFN-Gamma Signaling in Cancer (Deadline: 31 December 2024)
- CAR T Cells in Lymphoma and Multiple Myeloma (Deadline: 31 January 2025)
- Immunoediting in Cancer Therapies (Deadline: 13 April 2025)
Topical Collections
Following topical collections within this section are currently open for submissions:
